[breadcrumb_custom]

Evelo Biosciences Inc (NASDAQ: EVLO) Stock’s Performance and Current Analyst Sentiments

In the latest trading session, 0.45 million Evelo Biosciences Inc (NASDAQ:EVLO) shares changed hands as the company’s beta touched 1.85. With the company’s most recent per share price at $0.55 changing hands around $0.06 or 10.37% at last look, the market valuation stands at $10.34M. EVLO’s current price is a discount, trading about -8190.91% off its 52-week high of $45.60. The share price had its 52-week low at $0.30, which suggests the last value was 45.45% up since then. When we look at Evelo Biosciences Inc’s average trading volume, we note the 10-day average is 1.94 million shares, with the 3-month average coming to 630.14K.

Analysts gave the Evelo Biosciences Inc (EVLO) stock a consensus recommendation rating of an Underweight, calculated at a mean rating of 4.00. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended EVLO as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Evelo Biosciences Inc’s EPS for the current quarter is expected to be -$0.97.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.

Sponsored

Evelo Biosciences Inc (NASDAQ:EVLO) trade information

Instantly EVLO is in green as seen in intraday trades today. With action 65.52%, the performance over the past five days has been green. The jump to weekly highs of 0.7600 on Friday, 11/17/23 added 10.37% to the stock’s daily price. The company’s shares are showing year-to-date downside of -98.30%, with the 5-day performance at 65.52% in the green. However, in the 30-day time frame, Evelo Biosciences Inc (NASDAQ:EVLO) is -31.73% down. Looking at the short shares, we see there were 0.16 million shares sold at short interest cover period of 0.56 days.

The consensus price target for the stock as assigned by Wall Street analysts is $10.00, meaning bulls need an upside of 94.5% from its recent market value. According to analyst projections, EVLO’s forecast low is $10.00 with $10.00 as the target high. To hit the forecast high, the stock’s price needs a -1718.18% plunge from its current level, while the stock would need to soar -1718.18% for it to hit the projected low.

Evelo Biosciences Inc (EVLO) estimates and forecasts

Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Evelo Biosciences Inc will rise 82.70%, while the growth in revenue is estimated to hit 80.20% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.69%. The 2023 estimates are for Evelo Biosciences Inc earnings to increase by 91.37%.

EVLO Dividends

Evelo Biosciences Inc is expected to release its next quarterly earnings report on November 09.

Evelo Biosciences Inc (NASDAQ:EVLO)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.05% of Evelo Biosciences Inc shares while 76.77% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.81%. There are 76.77% institutions holding the Evelo Biosciences Inc stock share, with Flagship Pioneering Inc. the top institutional holder. As of Sep 29, 2023, the company held 41.90% of the shares, roughly 7.93 million EVLO shares worth $4.27 million.

FMR, LLC holds the second largest percentage of outstanding shares, with 12.92% or 2.45 million shares worth $1.32 million as of Sep 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares NASDAQ Biotechnology ETF. With 0.1 million shares estimated at $56288.0 under it, the former controlled 0.55% of total outstanding shares. On the other hand, iShares NASDAQ Biotechnology ETF held about 0.34% of the shares, roughly 64761.0 shares worth around $34867.0.

On Key

Related Posts